Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Abraham, E.; Reinhart, K.; Opal, S.; Demeyer, I.; Doig, C.; Rodriguez, A.; Beale, R.; Svoboda, P.; Laterre, P.; Simon, Stuart; Light, B.; Spapen, H.; A. Stone, Judy; Seibert, A.; Peckelsen, C.; De Deyne, C.; Postier, R.; Pettilä, V.; Sprung, C.; Artigas, A.; R. Percell, Sandra; Shu, V.; Zwingelstein, C.; Tobias, J.; Poole, L.; Stolzenbach, J.; Creasey, A.

doi:10.1001/JAMA.290.2.238

Public

Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis

Shared by NobleBlocks on Jul 8, 2003 • 12:00 AM UTC

Authors:

Edward Abraham

Konrad Reinhart

Steven M. Opal

Abstract

CONTEXT: The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis. Tissue factor pathway inhibitor (TFPI) forms a complex with tissue factor and blood protease factors leading to inhibition of thrombin generation and fibrin formation. O...

Subject

Medicine

Placebo

Sepsis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!